HealthcarePharmaceuticals & BiotechnologyPharmaceuticals

Brooks Laboratories Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 42 filings·Updated 12 Oct 2026
Showing 10 of 42 filings.
12 Oct 20262 filings
Company UpdatePrice movement

Significant movement in price has been observed in Brooks Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 18:10View Source
Company UpdateClarification

The Exchange has sought clarification from Brooks Laboratories Ltd on October 12, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 17:35
22 Sept 20261 filing
Insider Trading / SASTClosure of Trading Window

Brooks Laboratories Ltd – Trading Window closed from 1 October 2026 until 48 hours after the declaration of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30 September 2026

Brooks Laboratories Ltd – Trading Window closed from 1 October 2026 until 48 hours after the declaration of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30 September 2026

Filed 18:24View Source
16 Sept 20263 filings
Company UpdateChange in Directorate

Brooks Laboratories Announces Resignation of Company Secretary and Compliance Officer Krutika Rane, effective Oct 9, 2026

Resignation of KMP

  • Resignation of Krutika Rane as Company Secretary and Compliance Officer, effective 9 Oct 2026, to pursue another career.
Filed 19:06View Source
Company UpdateChange in Directorate

Brooks Laboratories Limited has informed the Exchange about Resignation of Director/KMP/SMP

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 18:57View Source
Company UpdateNewspaper Publication

Newspaper Publication regarding re-lodgement of transfer deed.

No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
Filed 13:04View Source
3 Sept 20261 filing
AGM/EGMAGM

Brooks Laboratories holds VC/OAVM 24th AGM; approves financials, RPTs, director reappointment, and executive remuneration

AGM Details

  • Date, time and mode: 3 September 2026, 9:00 AM, VC/OAVM.

Key Resolutions

  • Adoption of annual audited standalone and consolidated financial statements.
  • Re-appointment of director retiring by rotation.
  • Ratification of remuneration of cost auditors.
  • Approval and ratification of related party transactions.
  • Approval of related party transactions.
  • Remuneration to President – Strategy under section 188(1)(f).
  • Remuneration to President – Trading under section 188(1)(f).

Voting Results

  • Resolution 1: voting results not disclosed in filing.
  • Resolution 2: voting results not disclosed in filing.
  • Resolution 3: voting results not disclosed in filing.
  • Resolution 4: voting results not disclosed in filing.
  • Resolution 5: voting results not disclosed in filing.
  • Resolution 6: voting results not disclosed in filing.
  • Resolution 7: voting results not disclosed in filing.

Director Changes

  • Director re-appointment: Jitendrapratap Singh (DIN 09796568) by rotation.

Auditors

  • Cost auditor remuneration ratified.

Related Party Transactions

  • RPT approvals/ratifications sought; counterparty details not disclosed.
Filed 15:52View Source
22 Aug 20261 filing
Company UpdateNewspaper Publication

Please find enclosed herewith Addendum to the Notice of 24th Annual General Meeting.

No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
Filed 14:02View Source
21 Aug 20262 filings
AGM/EGMAGM

Brooks Laboratories updates AGM notice to modify related party transactions and corporate guarantee resolutions

AGM Details

  • AGM scheduled for 3 September 2026 at 9:00 AM IST via VC/OAVM.
  • Addendum dated 21 August 2026 clarifies Resolution No. 4.

Resolutions proposed

  • Resolution 2 (Ordinary): adopt Annual Report 2025-26.
  • Resolution 4 (Special): modify related party transactions and corporate guarantees; to be approved by addendum.

Related party transactions

  • Addendum aligns related party arrangements with corporate guarantees.

Voting/other outcomes

  • Voting results are not disclosed in the addendum.

Other material approvals

  • No additional material approvals stated beyond the Resolution 4 amendment.
Filed 16:54View Source
OthersReg. 34 (1) Annual Report

Brooks Laboratories FY2025-26: Standalone revenue Rs 8,573.84 lakh; PAT Rs 577.43 lakh; no dividend; strong cash flow

Financial performance

  • Revenue from operations: Rs 8,573.84 lakh; up 3.85% YoY.
  • Total income: Rs 8,690.89 lakh; up 4.16% YoY.
  • PBDIT: Rs 823.02 lakh; improved over prior year.
  • PBT: Rs 580.50 lakh; growth ~79.86%.
  • PAT: Rs 577.43 lakh; growth ~90.33%.
  • EPS: Rs 1.97 per share.
  • Cost of materials consumed: Rs 4,961.22 lakh; employee benefits Rs 1,516.21 lakh.
  • Finance costs: Rs 83.53 lakh; depreciation: Rs 158.99 lakh.
  • Net cash from operating activities: Rs 929.34 lakh.

Operations & growth

  • Materials cost reduced; procurement efficiency improving gross margins.
  • Employee benefits rose to Rs 1,516.21 lakh amid manpower expansion.
  • SPOT tenders secured; Lebanon and Sudan opportunities executed.
  • Export focus on semi-regulated markets; stronger international registrations.

Capital structure & liquidity

  • Total debt Rs 727.76 lakh; equity Rs 12,084.40 lakh; gearing 6.02%.
  • Cash and cash equivalents Rs 658.79 lakh.
  • Current ratio 1.72x.
  • Cash flow from operations Rs 929.34 lakh.

Dividend & capital allocation

  • Dividend for FY2025-26 not recommended.
  • CSR provisions not applicable; reserves unchanged.

Governance & leadership

  • Jitendra Pratap Singh to be reappointed as director.
  • Prashant Rathi appointed CEO from 1 June 2026; previously CFO.
  • ABRIDGE SPECIALITY LIMITED incorporated on 2 July 2026.

Strategic focus & markets

  • Strategy emphasizes semi-regulated markets, product registrations, Beta-lactam portfolio.
  • Post-year: Brooks Steriscience stake sale; 32.67% holding.

Audit, risk & compliance

  • Auditors: DMKH & Co; no qualification; IFCs adequate.
  • Cost Auditor remuneration Rs 60,000 plus taxes.
  • Independent directors declared independence; annual secretarial audit conducted.
Filed 16:51View Source
Showing 10 of 42 filings